Paper29370992
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
D'Angelo SP and 10 others. Lancet Oncol, 2018. Cited by 630 papers, by iCite.
Cite this record
ConductScience Library. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Papers, record 29370992. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29370992
- Disease
- sarcoma179 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
- PubMed
- Publication types
- Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Immunological | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Ipilimumab | Major topic |
| Nivolumab | Major topic |
| Sarcoma | Major topic |
| Soft Tissue Neoplasms | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Time Factors | |
| Treatment Outcome | |
| United States | |
| Young Adult |
Source PubMed
Grants14
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| U10 CA180821 | NCI NIH HHS | United States | U10CA180821 | PubMed and NIH | NIH RePORTER |
| U10 CA041287 | NCI NIH HHS | United States | U10CA041287 | PubMed and NIH | NIH RePORTER |
| U10 CA077651 | NCI NIH HHS | United States | U10CA077651 | PubMed and NIH | NIH RePORTER |
| U10 CA180882 | NCI NIH HHS | United States | U10CA180882 | PubMed and NIH | NIH RePORTER |
| U10 CA180833 | NCI NIH HHS | United States | U10CA180833 | PubMed and NIH | NIH RePORTER |
| U10 CA047642 | NCI NIH HHS | United States | U10CA047642 | PubMed and NIH | NIH RePORTER |
| U10 CA045808 | NCI NIH HHS | United States | U10CA045808 | PubMed and NIH | NIH RePORTER |
| U10 CA007968 | NCI NIH HHS | United States | U10CA007968 | PubMed and NIH | NIH RePORTER |
| U10 CA180836 | NCI NIH HHS | United States | U10CA180836 | PubMed and NIH | NIH RePORTER |
| UG1 CA189858 | NCI NIH HHS | United States | UG1CA189858 | PubMed and NIH | NIH RePORTER |
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH | NIH RePORTER |
| U10 CA077440 | NCI NIH HHS | United States | U10CA077440 | PubMed and NIH | NIH RePORTER |
| U10 CA180791 | NCI NIH HHS | United States | U10CA180791 | PubMed and NIH | NIH RePORTER |
| P30CA086862 | NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02500797 | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 29370991 | A start towards immunotherapy in sarcomas? | https://conductscience.org/library/papers/29370991 |
Source PubMed
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26874885 | Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. | Lancet | 2016 | https://conductscience.org/library/papers/26874885 | PubMed |
| 2 | 23724867 | Nivolumab plus ipilimumab in advanced melanoma. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23724867 | PubMed |
| 3 | 20004617 | Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. | Lancet Oncol | 2010 | https://conductscience.org/library/papers/20004617 | PubMed |
| 4 | 20160101 | PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. | Proc Natl Acad Sci U S A | 2010 | https://conductscience.org/library/papers/20160101 | PubMed |
| 5 | 26952546 | Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. | Lancet | 2016 | https://conductscience.org/library/papers/26952546 | PubMed |
| 6 | 22595799 | Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. | Lancet | 2012 | https://conductscience.org/library/papers/22595799 | PubMed |
| 7 | 25428505 | PD-1 blockade induces responses by inhibiting adaptive immune resistance. | Nature | 2014 | https://conductscience.org/library/papers/25428505 | PubMed |
| 8 | 25765070 | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. | Science | 2015 | https://conductscience.org/library/papers/25765070 | PubMed |
| 9 | 27592805 | Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27592805 | PubMed |
| 10 | 2702835 | Optimal two-stage designs for phase II clinical trials. | Control Clin Trials | 1989 | https://conductscience.org/library/papers/2702835 | PubMed |
| 11 | 25891304 | Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25891304 | PubMed |
| 12 | 23554566 | A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. | Sarcoma | 2013 | https://conductscience.org/library/papers/23554566 | PubMed |
| 13 | 28440953 | Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. | Cancer | 2017 | https://conductscience.org/library/papers/28440953 | PubMed |
| 14 | 27291997 | Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. | Lancet | 2016 | https://conductscience.org/library/papers/27291997 | PubMed |
| 15 | 22437870 | The blockade of immune checkpoints in cancer immunotherapy. | Nat Rev Cancer | 2012 | https://conductscience.org/library/papers/22437870 | PubMed |
| 16 | 20525992 | Improved survival with ipilimumab in patients with metastatic melanoma. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20525992 | PubMed |
| 17 | 26371143 | Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/26371143 | PubMed |
| 18 | 26712084 | Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. | Lancet | 2016 | https://conductscience.org/library/papers/26712084 | PubMed |
| 19 | 25795410 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/25795410 | PubMed |
| 20 | 1100130 | Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. | Biometrics | 1975 | https://conductscience.org/library/papers/1100130 | PubMed |
Cited by480
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 630 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42958422 | Tazemetostat combined PD-1 inhibitor achieving prolonged survival in primary proximal epithelioid sarcoma: a case report and review of the literature. | J Med Case Rep | 2026 | https://conductscience.org/library/papers/42958422 | PubMed |
| 42939993 | CD47-SIRPα as a Therapeutic Target in Sarcoma: A Systematic Review of Expression, Preclinical, and Clinical Evidence. | Biomedicines | 2026 | https://conductscience.org/library/papers/42939993 | PubMed |
| 42855246 | Pembrolizumab plus lenvatinib in the treatment of unresectable cutaneous angiosarcoma: a study protocol of multicentre, open-label phase II study (NCCH2213, PLAS). | BMJ Open | 2026 | https://conductscience.org/library/papers/42855246 | PubMed |
| 42835191 | Advances in uterine sarcoma management: A mini-review of clinical practice and molecular insights. | Gynecol Oncol Rep | 2026 | https://conductscience.org/library/papers/42835191 | PubMed |
| 42826198 | An immunocompetent, multifluorescent resource for real-time analysis of osteosarcoma progression, metastasis, and response to therapy. | Sci Adv | 2026 | https://conductscience.org/library/papers/42826198 | PubMed |
| 42783458 | Pleomorphism in Soft Tissue Sarcomas: Molecular Characteristics and Clinical Features. | Med Sci (Basel) | 2026 | https://conductscience.org/library/papers/42783458 | PubMed |
| 42769412 | Rule-derived preoperative inflammatory-lymphocyte recovery phenotype and pathological response in resected osteosarcoma: a retrospective cohort study. | Front Immunol | 2026 | https://conductscience.org/library/papers/42769412 | PubMed |
| 42707561 | Dynamic immune state transitions and metastatic niche remodelling drive osteosarcoma evolution as a barrier-restricted immune-cold ecosystem. | Front Immunol | 2026 | https://conductscience.org/library/papers/42707561 | PubMed |
| 42675610 | Real-world experience with ipilimumab in combination with nivolumab in advanced sarcoma: a retrospective analysis including ultra-rare sarcomas. | Oncologist | 2026 | https://conductscience.org/library/papers/42675610 | PubMed |
| 42650028 | Epithelioid Sarcoma: A Review and Update. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42650028 | PubMed |
| 42569618 | Complete Response to Pembrolizumab in Radiation-Induced Undifferentiated Pleomorphic Sarcoma of the Face: A Case Report and Review of the Literature. | Case Rep Oncol | 2026 | https://conductscience.org/library/papers/42569618 | PubMed |
| 42558163 | Osteosarcoma as a communication-driven disease: redefining tumor-bone signaling networks as therapeutic targets. | Front Oncol | 2026 | https://conductscience.org/library/papers/42558163 | PubMed |
| 42556071 | Chondrosarcoma: A comprehensive review of tumor biology, clinical behavior, and therapeutic advances. | Cancer Treat Rev | 2026 | https://conductscience.org/library/papers/42556071 | PubMed |
| 42529121 | Recurrent retroperitoneal sarcoma: beyond resectability toward a biology-based therapeutic framework. | Oncol Rev | 2026 | https://conductscience.org/library/papers/42529121 | PubMed |
| 42527032 | Complete response to dual immune checkpoint blockade in a patient with Birt-Hogg-Dubé syndrome and epithelioid angiomyolipoma. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42527032 | PubMed |
| 42525308 | Dedifferentiated Chondrosarcoma: Current Advances and Future Perspectives. | Curr Treat Options Oncol | 2026 | https://conductscience.org/library/papers/42525308 | PubMed |
| 42512423 | Pharmacologic Resistance in Soft Tissue Sarcomas: Mechanisms, Biomarkers, and Translational Therapeutic Strategies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42512423 | PubMed |
| 42505406 | Immunotherapy in Soft Tissue Sarcomas-An Ongoing Quest. | Cells | 2026 | https://conductscience.org/library/papers/42505406 | PubMed |
| 42494596 | Promising effects of high-intensity focused ultrasound combined with eribulin and sintilimab in a patient with advanced leiomyosarcoma: a case report and literature review. | Front Oncol | 2026 | https://conductscience.org/library/papers/42494596 | PubMed |
| 42352340 | Understanding and Overcoming Osteosarcoma Heterogeneity. | Biomolecules | 2026 | https://conductscience.org/library/papers/42352340 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ASPSCR1 | 79058 | PubTator's text mining | https://conductscience.org/library/genes/79058 | NCBI Gene |
| ATRX | 546 | PubTator's text mining | https://conductscience.org/library/genes/546 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| GPT | 2875 | PubTator's text mining | https://conductscience.org/library/genes/2875 | NCBI Gene |
| NOS1 | 4842 | PubTator's text mining | https://conductscience.org/library/genes/4842 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| IPILIMUMAB | CHEMBL1789844 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1789844 | ChEMBL |
| NIVOLUMAB | CHEMBL2108738 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2108738 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29370992
GET https://conductscience.org/api/papers/v1/29370992/references?page=2